The call highlighted a strong start to 2025, with significant progress in product launches and clinical trials. However, challenges remain with regulatory hurdles in Europe and ongoing competition from generics, balanced by strong cash reserves and strategic planning.

Company Guidance -

Q3 2025

During the PTC Therapeutics First Quarter 2025 Earnings Conference Call, the company provided updated guidance for the fiscal year 2025, narrowing its full-year revenue expectations to between $650 million and $800 million. In the first quarter, PTC achieved $190 million in total revenue, driven by strong contributions from its Duchenne muscular dystrophy (DMD) franchise, which generated $134 million. Additionally, the company highlighted a robust cash position of over $2 billion, which supports ongoing commercial and R&D activities as PTC moves towards cash flow breakeven. PTC is preparing for the anticipated global launch of SUFIANCE, a treatment for phenylketonuria (PKU), with expected revenue contributions from European markets in 2025. The company is also pursuing regulatory approvals for SUFIANCE in the U.S. and other products like vatiquinone for Friedreich’s ataxia.

Strong Start to 2025 with $190 Million Revenue

PTC Therapeutics achieved $190 million of revenue in the first quarter of 2025, with strong contributions from the DMD franchise.

SUFIANCE's Anticipated Global Launch

Positive CHMP opinion on SUFIANCE marketing authorization with an expected broad label for all PKU patients. Preparations for European and U.S. launches are underway, aiming for over $1 billion in revenue.

PTC518 Huntington’s Disease Program Success

The PIVOT HT Phase 2 study met its primary endpoints of blood HTT lowering and safety, with continued trends of dose-dependent favorable clinical effects after 24 months of treatment.

Strong Cash Position

PTC closed the first quarter with over $2 billion in cash, allowing support for all planned commercial and R&D activities without needing additional capital.

Vatiquinone NDA Progress

FDA review of vatiquinone for Friedreich’s ataxia is progressing well, with no plans for an AdCom meeting, indicating confidence in the approval process.

DMD Franchise Revenue Defense

Delivered strong first-quarter revenue of $134 million for the global DMD franchise, demonstrating effective defense strategies despite challenges.

PTC Therapeutics (PTCT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PTCT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	-1.03 / -	-1.39	―	―	―
Aug 07, 2025	2025 (Q2)	-1.02 / -0.83	-1.29	35.66% (+0.46)	―
May 06, 2025	2025 (Q1)	-1.01 / 10.04	-1.2	936.67% (+11.24)	―
Feb 27, 2025	2024 (Q4)	-0.54 / -0.85	-2.06	58.74% (+1.21)	―
Nov 07, 2024	2024 (Q3)	-1.52 / -1.39	-1.76	21.02% (+0.37)	―
Aug 08, 2024	2024 (Q2)	-1.12 / -1.29	-2.66	51.50% (+1.37)	―
Apr 25, 2024	2024 (Q1)	-1.27 / -1.20	-1.88	36.17% (+0.68)	―
Feb 29, 2024	2023 (Q4)	-0.14 / -2.06	-2.35	12.34% (+0.29)	―
Oct 26, 2023	2023 (Q3)	-1.06 / -1.76	-1.53	-15.03% (-0.23)	―
Aug 03, 2023	2023 (Q2)	-1.62 / -2.66	-2.13	-24.88% (-0.53)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PTCT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$50.36	―	―
May 06, 2025	$36.19	$40.76	+12.63%
Feb 27, 2025	$50.57	$55.26	+9.27%
Nov 07, 2024	$42.96	$44.28	+3.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does PTC Therapeutics (PTCT) report earnings?

PTC Therapeutics (PTCT) is schdueled to report earning on Oct 23, 2025, After Close (Confirmed).

What is PTC Therapeutics (PTCT) earnings time?

PTC Therapeutics (PTCT) earnings time is at Oct 23, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PTCT EPS forecast?

PTCT EPS forecast for the fiscal quarter 2025 (Q3) is -1.03.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing